Medtronic received information via literature regarding a single-center experience on complete transcatheter repair of a degenerated mitral bioprosthesis.All data were collected from a single center between march 2012 to october 2012.The study population included 5 patients (predominantly male; mean age 73 years), 1 patient had been previously implanted with medtronic mosaic valve and all were implanted valve-in-valve with medtronic melody valves.The serial numbers were not provided.Medtronic received information that (b)(6) year-old male patient had been implanted with a 29 mm medtronic mosaic valve and two occluders were implanted for paravalvular leak (pvl).Six-months post implant, a 24 mm medtronic melody valve was implanted valve-in-valve (viv) due to severe stenosis and regurgitation.Mild paravalvular leak (pvl) was noted post-implant.No additional adverse patient effects were reported.Medtronic received information that (b)(6)-year-old male patient had been implanted with a non-medtronic valve into mitral position and two occluders were implanted for paravalvular leak (pvl).Eleven years post implant, a 24 mm medtronic melody valve was implanted valve-in-valve due to severe regurgitation and mitral stenosis.Embolization of the melody valve was noted post-implant.An attempt was made to secure the valve in place using a second melody valve (melody viv) without success.The valves were surgically replaced with a non-medtronic valve without complication.No additional adverse patient effects were reported.No additional adverse patient effects or product performance issues were reported.
|